At the 2026 Cell-Cell Symposium at UCLA, Partillion Bioscience highlighted its role in advancing a new era of cell-cell interaction mapping. Joe de Rutte, CEO of Partillion Bioscience, presented how ...
Researchers from the Earlham Institute, in collaboration with the Department of Biology at the University of Oxford, have ...
Scientists have long observed that embryos of different species within a phylum look quite distinct at early and late ...
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to partner with Moonlight Bio, a pioneering leader ...
Sana Biotechnology’s investigational allogeneic islet cell therapy has survived and secreted insulin for more than one year ...
Oxford, UK - March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing a clinical-stage allogeneic cell therapy. The layoffs are expected to be ...
Pharmaceutical Technology on MSN
Quintessence debuts first ‘living’ artificial cell for CGT bio-separation
The technology is designed to simplify the bio-separation process while reducing manufacturing costs.
Tevogen Bio files patent for T cell vaccine targeting entire viral genome, enhancing immune response against mutations and viral infections. Tevogen Bio, a clinical-stage immunotherapy biotech company ...
Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results